Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | PRNP | P04156 | 1/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 5/20 | 0.36 |
| ▸ | EGFR | P00533 | 3/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10188138 | 0.92 | RAB9A (0.42) | RAB9ANPC1MAPTCHRM1HTR2A | |
| SCHEMBL10188133 | 0.78 | NPC1 (0.37) | RAB9ANPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL508843 | 0.78 | MAPK13 (0.40) | RAB9ANPC1MAPTMCHR1MAPK13 | |
| SCHEMBL508844 | 0.78 | MAPK13 (0.40) | RAB9ANPC1MAPTMCHR1MAPK13 | |
| SCHEMBL13360642 | 0.70 | NPC1 (0.38) | RAB9ANPC1MAPTMAPK13MAPK12 | |
| SCHEMBL508873 | 0.69 | MAPK14 (0.46) | RAB9ANPC1MAPTMAPK13MAPK12 | |
| SCHEMBL508872 | 0.69 | MAPK14 (0.46) | RAB9ANPC1MAPTMAPK13MAPK12 | |
| SCHEMBL10188135 | 0.68 | MAPK14 (0.62) | MAPK13MAPK12MAPK11MAPK14EGFR | |
| SCHEMBL10188128 | 0.66 | MAPK14 (0.41) | RAB9ANPC1MAPTMAPK13MAPK12 | |
| SCHEMBL509131 | 0.66 | MAPK13 (0.35) | RAB9ANPC1CHRM1MCHR1MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113520-A1 | KINASE KNOCKDOWN VIA ELECTROPHILICALLY ENHANCED INHIBITORS | PRINCIPIA BIOPHARMA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113520-A1 | KINASE KNOCKDOWN VIA ELECTROPHILICALLY ENHANCED INHIBITORS | MAP3K20, MAP3K6, MAP3K19 | RAB9A 2042/4885NPC1 2962/4885MAPT 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.